Medication info
Ezatine Tablets 5 Milligrams (Memantine Hydrochloride)

Ezatine Tablets 5 Milligrams (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›5mg / 1 tablet
Manufacturer / importer
Albohealth Korea Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202502973 · Approved 2025.11.18

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This drug is administered orally once daily, at the same time each day. If needed, this drug may be administered twice daily. This drug may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1–7): Administer 5mg once daily for 7 days. Week 2 (days 8–14): Administer 10mg once daily for 7 days. Week 3 (days 15–21): Administer 15mg once daily for 7 days. From week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, the dose may be increased to 20mg daily at least 7 days after administration, according to the standard dose-titration schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.

Ingredients

Manufacturer
Albohealth Korea Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of moderate to severe Alzheimer's disease. Alzheimer's disease is a condition that causes a decline in memory and cognitive function, and this medication helps alleviate the symptoms and improve the patient's daily living abilities. Consistent treatment contributes to the improvement of the patient's quality of life.

How to take

Adult dose

This drug is administered orally once daily, at the same time each day. If needed, this drug may be administered twice daily. This drug may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1–7): Administer 5mg once daily for 7 days. Week 2 (days 8–14): Administer 10mg once daily for 7 days. Week 3 (days 15–21): Administer 15mg once daily for 7 days. From week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, the dose may be increased to 20mg daily at least 7 days after administration, according to the standard dose-titration schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.

Precautions

This medicine should not be administered to patients with an allergy to any of its ingredients. It should also not be used in patients with severely impaired liver function or significantly decreased kidney function. Patients with epilepsy or a history of seizures, or those who have a propensity to develop epilepsy, should use this medication with caution. In particular, concomitant use with medications such as amantadine, ketamine, and dextromethorphan may increase central nervous system side effects, and thus should be avoided. Patients with conditions that may cause changes in urinary acidity (pH) or dietary changes should be closely monitored when taking this medication. Patients with myocardial infarction, congestive heart failure, or uncontrolled hypertension do not have sufficient safety data for this medication, so it should be administered cautiously. Taking this medication may cause side effects such as dizziness, headache, constipation, drowsiness, and hypertension. Psychological confusion, hallucinations, and psychotic symptoms may rarely occur, so if symptoms arise, consultation with healthcare personnel is necessary. This medication may interact with other drugs, so it is essential to inform your healthcare provider about any medications currently being taken. In particular, monitoring is required when taken with antipsychotics, skeletal muscle relaxants, or anticoagulants. Pregnant women or those who may become pregnant should consult with a physician before taking this medication. If breastfeeding, it is recommended to discontinue breastfeeding as this medication may pass into breast milk. The safety and efficacy of this medication have not been established for children and adolescents under 18 years, so its use is discouraged. In cases of overdose, severe symptoms such as coma, hallucination, seizures, and vomiting may occur, necessitating immediate medical attention, and there is no specific antidote. This medication may slow the patient's reaction speed, requiring caution when driving or operating machinery. Finally, keep out of the reach of children and do not transfer to other containers for safety.

Side effects

  • dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug allergy reaction
  • confusion
  • hallucination
  • psychotic reaction
Show 19 more
  • balance disorder
  • gait abnormality
  • seizure
  • heart failure
  • venous thrombosis/thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver function test values
  • hepatitis
  • fatigue
  • abnormal confusion
  • sleepiness
  • restlessness
  • aggression
  • gait disturbance
  • visual hallucination
  • stupor
  • unconsciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C to ensure the medication retains its effect and prevents deterioration.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.